By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Syros Pharmaceuticals 

480 Arsenal Street
Suite 130
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-744-1340 Fax: n/a


We are a therapeutics company passionately committed to applying our scientific leadership in the emerging field of gene control to transform the lives of patients with cancer and other diseases.

Founded by world-leading experts in gene regulation, and led by a seasoned management team, Syros is focused on developing new medicines that control genes that cause disease. Central to our approach is a proprietary drug development platform of integrated gene control assay technologies, computational biology, chemistry, and deep biologic insights that gives us an unprecedented understanding of and control over gene regulation. Our pioneering research and drug development capabilities provide us with the distinctive ability to identify new, important disease and patient-targeted gene control medicines.

Key Statistics

Ownership: Private

Web Site: Syros Pharmaceuticals


Company News
Syros Pharmaceuticals To Present On Its Two Lead Programs, SY-1425 And SY-1365, At 21st Congress Of The European Hematology Association 5/19/2016 12:11:16 PM
Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity Of Its Selective CDK7 Inhibitor In Preclinical Models Of Acute Myeloid Leukemia 4/20/2016 11:28:30 AM
Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Cancer Activity Of SY-1425 In Preclinical Models Of Acute Myeloid Leukemia 4/18/2016 10:49:13 AM
Syros Pharmaceuticals To Present At 15th Annual Needham Healthcare Conference 4/6/2016 9:40:59 AM
Syros Pharmaceuticals To Present Preclinical Data On SY-1425 And CDK7 Inhibitor Program In Blood Cancers At Upcoming AACR Annual Meeting 3/17/2016 9:44:24 AM
Syros Pharmaceuticals To Participate In Two Upcoming Conferences 3/3/2016 10:41:33 AM
Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing 1/13/2016 10:26:00 AM
Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity Of First-In-Class Selective CDK7 Inhibitor In Models Of Acute Leukemias 12/7/2015 1:51:04 PM
Syros Pharmaceuticals Appoints David A. Roth, M.D., As Chief Medical Officer 12/7/2015 11:00:19 AM
Syros Pharmaceuticals Announces Issuance Of U.S. Patents Related To Its Gene Control Drug Discovery And Development Platform 11/10/2015 11:15:51 AM